{"id":"dw6012-dasidiem-tab-10-100mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Pleural effusion"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dasatinib is a multi-targeted tyrosine kinase inhibitor that blocks BCR-ABL and other kinases implicated in hematologic malignancies. The 10/100 mg formulation suggests a combination product, likely pairing dasatinib with a complementary agent to enhance efficacy or tolerability in chronic myeloid leukemia or acute lymphoblastic leukemia.","oneSentence":"DW6012 is a fixed-dose combination of dasatinib and another agent that inhibits tyrosine kinases to suppress abnormal cell proliferation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:32:00.919Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML)"},{"name":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)"}]},"trialDetails":[{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Piotazone tab.","Sitdiem tab. 100mg"],"phase":"marketed","status":"active","brandName":"DW6012(Dasidiem tab. 10/100mg)","genericName":"DW6012(Dasidiem tab. 10/100mg)","companyName":"Dong Wha Pharmaceutical Co. Ltd.","companyId":"dong-wha-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DW6012 is a fixed-dose combination of dasatinib and another agent that inhibits tyrosine kinases to suppress abnormal cell proliferation. Used for Chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}